Therapeutic potential of flavonols in the treatment of JCPyV

Evan MacLure1, Kaitlin Garabian1, Bethany A O'Hara1

  • 1Department of Cell Biology, Biochemistry, and Molecular Biology, Brown University, Providence, Rhode Island, USA.

Microbiology Spectrum
|August 21, 2025
PubMed

Insights

Flavonols like quercetin show promise in fighting JC polyomavirus (JCPyV) infection, which causes the deadly PML disease. These compounds inhibit viral entry and spread in human glial cells, offering potential new antiviral therapies.

Area of Science:

  • Virology
  • Neuroscience
  • Pharmacology

Background:

  • JC polyomavirus (JCPyV) causes progressive multifocal leukoencephalopathy (PML), a severe demyelinating disease.
  • Current PML treatments are limited, often focusing on immune reconstitution.
  • There are no approved antiviral drugs specifically for JCPyV-induced disease.

Purpose of the Study:

  • To investigate the antiviral potential of flavonols against JCPyV infection.
  • To determine if flavonols can inhibit both initial JCPyV infection and viral spread.

Main Methods:

  • Treatment of human glial cells with specific flavonols (quercetin, myricetin, fisetin).
  • Assessment of JCPyV infection levels and viral spread following flavonol treatment.
  • In vitro studies using glial cell lines and normal human glial cells.

Main Results:

  • Quercetin, myricetin, and fisetin significantly reduced JCPyV infection in human glial cells.
  • Quercetin and fisetin demonstrated efficacy in suppressing viral spread in established infections.
  • Flavonols inhibited both initial JCPyV infection and subsequent viral dissemination.

Conclusions:

  • Flavonols represent a promising new class of therapeutic agents against JCPyV.
  • Quercetin and fisetin show potential as viable antiviral drugs for PML.
  • Further research is needed to elucidate the mechanism of action and blood-brain barrier penetration.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
256
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
248
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
252
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
224
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
55